AKIKI2研究:急性肾损伤肾脏替代治疗启动时机的随机对照试验方案
AKIKI2是一项前瞻性、多中心、开放标签、两臂随机试验,比较AKIKI试验中的延迟策略(现称标准策略,12小时内启动RRT)与进一步延迟策略(仅出现严重并发症或血清尿素达50 mmol/L时启动RRT)。主要结局为第28天无RRT天数,计划观察810例、随机化270例。
要点
- 重症AKI患者若血清尿素>40 mmol/L或寡尿/无尿>72小时,可随机分组比较RRT启动时机。
- 进一步延迟策略仅在出现严重高钾、酸中毒、肺水肿或尿素达50 mmol/L时启动RRT。
- 主要结局为第28天无RRT天数,需关注延迟策略对RRT使用和费用的影响。
核心结论
- AKIKI2研究旨在比较标准延迟策略与进一步延迟策略对重症AKI患者RRT启动的影响。
研究设计与样本
- 前瞻性、多中心、开放标签、两臂随机试验,包括观察阶段和随机化阶段。
- 计划观察阶段纳入810例患者,随机化270例受试者。
关键数值与推荐
- 纳入标准:接受或曾接受静脉儿茶酚胺和/或侵入性机械通气,KDIGO分期3级AKI,且无潜在严重情况。
- 随机化标准:血清尿素浓度>40 mmol/L和/或寡尿/无尿超过72小时。
- 标准策略:随机后12小时内启动RRT;延迟策略:仅出现严重高钾、严重代谢或混合性酸中毒、液体过负荷所致急性肺水肿伴严重低氧血症,或血清尿素达50 mmol/L时启动RRT。
- 主要结局:第28天无RRT天数。
临床怎么用
- 对于重症AKI患者,在无严重高钾、酸中毒或肺水肿时,可考虑延迟RRT直至尿素>40 mmol/L或寡尿/无尿>72小时。
- 进一步延迟至尿素达50 mmol/L可能减少RRT使用,但需密切监测严重并发症。
局限性
- 研究方案尚未报告结果,无法评估延迟策略的安全性和有效性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The Artificial Kidney Initiation in Kidney Injury (AKIKI) trial showed that a delayed renal replacement therapy (RRT) strategy for severe acute kidney injury (AKI) in critically ill patients was safe and associated with major reduction in RRT initiation compared with an early strategy. The five criteria which mandated RRT initiation in the delayed arm were: severe hyperkalemia, severe acidosis, acute pulmonary edema due to fluid overload resulting in severe hypoxemia, serum urea concentration > 40 mmol/l and oliguria/anuria > 72 h. However, duration of anuria/oliguria and level of blood urea are still criteria open to debate. The objective of the study is to compare the delayed strategy used in AKIKI (now termed "standard") with another in which RRT is further delayed for a longer period (termed "delayed strategy"). METHODS/DESIGN: This is a prospective, multicenter, open-label, two-arm randomized trial. The study is composed of two stages (observational and randomization stages). At any time, the occurrence of a potentially severe condition (severe hyperkalemia, severe metabolic or mixed acidosis, acute pulmonary edema due to fluid overload resulting in severe hypoxemia) suggests immediate RRT initiation. Patients receiving (or who have received) intravenously administered catecholamines and/or invasive mechanical ventilation and presenting with AKI stage 3 of the KDIGO classification and with no potentially severe condition are included in the observational stage. Patients presenting a serum urea concentration > 40 mmol/l and/or an oliguria/anuria for more than 72 h are randomly allocated to a standard (RRT is initiated within 12 h) or a delayed RRT strategy (RRT is initiated only if an above-mentioned potentially severe condition occurs or if the serum urea concentration reaches 50 mmol/l). The primary outcome will be the number of RRT-free days at day 28. One interim analysis is planned. It is expected to include 810 patients in the observational stage and to randomize 270 subjects. DISCUSSION: The AKIKI2 study should improve the knowledge of RRT initiation criteria in critically ill patients. The potential reduction in RRT use allowed by a delayed RRT strategy might be associated with less invasive care and decreased costs. Enrollment is ongoing. Inclusions are expected to be completed by November 2019. TRIAL REGISTRATION: ClinicalTrials.gov, ID: NCT03396757. Registered on 11 January 2018.
引用
- Gaudry S, Hajage D, Martin-Lefevre L, et al. The Artificial Kidney Initiation in Kidney Injury 2 (AKIKI2): study protocol for a randomized controlled trial. Trials. 2019. PMID: 31843007. doi:10.1186/s13063-019-3774-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。